Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Determining IDH-Mutational Status in Gliomas Using IDH1-R132H Antibody and Polymerase Chain Reaction

25 Oct 2018

Abstract excerpt

Determination of the isocitrate dehydrogenase (IDH) mutation status, presence or absence of mutation in IDH genes (IDH1 or IDH2), has become one of the most important molecular features taken into account in the management of patients with diffuse gliomas. Tumors that are IDH-mutant have a better prognosis than their counterparts with similar histologic grade and IDH-wildtype phenotype. IDH1-R132H is the most...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glioma Diagnosis and Treatment
Share to Radiomics and Machine Learning in Medical Imaging

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30358614
DOI: 10.1097/pai.0000000000000702

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Determining IDH-Mutational Status in Gliomas Using IDH1-R132H Antibody and Polymerase Chain ReactionPMID 30358614Read ↗

IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee.Semantic proximity Read ↗

Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.Semantic proximity Read ↗

Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria.Semantic proximity Read ↗

Expanding the spectrum of IDH1 mutations in gliomas.Semantic proximity Read ↗

IDH mutations in older patients with diffuse astrocytic gliomas.Semantic proximity Read ↗

Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.Semantic proximity Read ↗

Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.Semantic proximity Read ↗

Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing.Semantic proximity Read ↗

IDH mutation analysis in gliomas as a diagnostic and prognostic biomarker.Semantic proximity Read ↗

The clinical use of IDH1 and IDH2 mutations in gliomasSemantic proximity Read ↗

A new sensitive PCR assay for one-step detection of 12 IDH1/2 mutations in glioma.Semantic proximity Read ↗

Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.